
|Articles|November 1, 2012
PDE-5 inhibitor use shows no effect on BPH therapy outcomes
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5











